Profil
Karl Richard Gibson is the founder and Chief Technology Officer of Ixchelsis Ltd.
which is founded in 2011.
He is also the founder of Sandexis LLP.
Dr. Gibson has an undergraduate and doctorate degree from the University of Cambridge.
Postes actifs de Karl Richard Gibson
Sociétés | Poste | Début |
---|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Fondateur | 27/07/2011 |
Sandexis LLP | Fondateur | - |
Formation de Karl Richard Gibson
University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
Sandexis LLP |